Business1 min read

Bayer reaches Roundup settlement that could cost the company billions

By · Via NPR · Published by Everything Blog

In short

The nationwide personal-injury resolution requires Bayer to disburse funds ranging from $10,000 to $165,000 per claimant based on occupational exposure and diagnostic age. This agreement builds upon a previous deal where the company paid between $10 billion and $11 billion to settle over 100,000 lawsuits. While Bayer removed glyphosate from American residential products, the weed-killer remains widely utilized in the agricultural sector. Meanwhile, the Environmental Protection Agency is continuing to review human health evidence regarding the chemical.

Key points

  • Bayer continues to maintain that its primary herbicide ingredient does not cause cancer d…: Bayer continues to maintain that its primary herbicide ingredient does not cause cancer despite paying out billions.
  • The company removed glyphosate from its United States residential market while maintainin…: The company removed glyphosate from its United States residential market while maintaining its active use in agriculture.
  • Regulatory agencies remain divided as the EPA reviews evidence and the World Health Organ…: Regulatory agencies remain divided as the EPA reviews evidence and the World Health Organization views glyphosate as probably carcinogenic.

Sources checked by our analysis pipeline: 1

The agrochemical and biotech giant Bayer has agreed to pay billions of dollars to people who sued the company alleging the weed-killer Roundup caused their cancer.

On Friday, a judge in Missouri gave final approval to the nationwide settlement that could cost the company up to $7.25 billion in the coming years.

The money will go to thousands of people who have been or will be diagnosed with non-Hodgkin lymphoma — a blood cancer that they claim is linked to glyphosate, which is the main ingredient in Roundup.

Under the settlement in circuit court, people affected could receive anywhere from $10,000 to $165,000 in compensation, depending on whether their work in agriculture or other occupations exposed them to higher levels of glyphosate, the age when they were diagnosed with non-Hodgkin lymphoma and other factors.

In a statement, the CEO of Bayer, Bill Anderson, called the settlement a "decisive milestone" that will "mitigate the risks" of pending and future litigation.

The presiding judge, Timothy Boyer, said it was "among the largest in the history of mass tort personal-injury class action settlements."

Business